We have examined observational data from four published studies investigating the incidence of postoperative silent myocardial ischaemia (post-SMI) for the effects of chronic intercurrent therapy with β-adrenoceptor blockade or chronic calcium channel entry blockade. A total of 453 patients underwent ambulatory ECG monitoring before and for 2 days after non-cardiac surgery; 79 patients were receiving chronic intercurrent β-adrenoceptor blockade and 70 calcium channel entry blockade for ischaemic heart disease or arterial hypertension. Using logistic regression analysis, we defined a model for post-SMI that included four significant terms: β-adrenoceptor blockade; calcium channel entry blockade; arterial hypertension; and vascular surgery. Using univariate regression, there was no effect of chronic β-adrenoceptor blocking therapy on post-SMI (odds ratio 0.94 (95% confidence intervals 0.54-1.65)), but there was a higher incidence of post-SMI in patients receiving chronic calcium channel entry blocking drugs (odds ratio 1.95 (1.15-3.32); Pϭ0.015). There was no interaction between β-adrenoceptor blockade and calcium channel entry blockade for postoperative SMI (odds ratio 2.48 (0.71-8.73)), but there was an interaction between β-adrenoceptor blockade, calcium channel entry blockade, hypertension and vascular surgery (Pϭ0.0201). These findings are at variance with those which have shown effects of preoperative β-adrenoceptor blockade on the incidence of post-SMI over the first 7 days after operation, and on mortality rates to 2 yr. There are no comparable data examining the effects of chronic intercurrent calcium channel entry blockade.
given either by slow i.v. infusion over 15 min or orally, blockade or calcium channel entry blockade. Odds ratios were derived for the association between postoperative SMI reduced the incidence of SMI over the first 7 days after operation (17% vs 34% over the first 2 days after operation and treatment. The statistical significance of these univariate associations was examined using chi-square tests for categor-(Pϭ0.008) and 24% vs 39% over the first 7 days after operation (Pϭ0.03)). 10 ical data. The association between postoperative SMI and other patient characteristics and cardiovascular variables In this study, we have retrospectively examined data from four observational studies of perioperative ambulatory ECG (sex, age Ͼ70 yr, history of smoking, vascular surgery, history of myocardial infarction or angina pectoris, history of arterial recording (aECG) from Oxford 3 4 5 11 to see if chronic intercurrent therapy with β-adrenoceptor blocking drugs or calcium hypertension based on a general practitioner diagnosis and institution of appropriate medication, diabetes mellitus, prechannel entry blockade reduced the incidence of postoperative SMI.
operative SMI) was examined in the same way. A probability of less than 5% was accepted as statistically significant.
Patients and methods
Data were analysed using logistic regression analysis (using Stata version 6.0 on a Viglen Pentium III 233 MHz After obtaining approval from the Local Ethics Committee microprocessor), where the terms for chronic intercurrent β-and informed consent, 455 patients undergoing urological adrenoceptor blockade or calcium channel entry blockade (nϭ93), orthopaedic (nϭ144), vascular or general abdominal were retained as the terms of interest. The influence of potensurgery (nϭ218) underwent ambulatory ECG monitoring tial confounders was examined and retained in the final model using Kontron Micro KI 5100 solid state digital recorders if they had a clinically significant impact on the coefficients before operation and for the first 2 days after operation. All for β-adrenoceptor blockade and calcium channel entry patients receiving chronic intercurrent medication (ജ1 month blockade. Statistical significance was determined using a logduration) continued this up to and including the morning of likelihood ratio test and the Wald test, and a probability of surgery, and recommenced as soon as feasible after the end of less than 5% was taken as significant. operation. β-Adrenoceptor blocking drugs used were mainly
The power of the study was calculated using the frequenatenolol, but some patients were receiving oxprenolol, bisopcies of postoperative SMI reported by Wallace and colrolol, propranolol, metoprolol, labetolol and sotalol. Simleagues. 10 We determined that groups of 79 patients receiving ilarly, most patients on chronic calcium channel entry β-adrenoceptor blockade and 374 unexposed controls would blockade were receiving nifedipine, although some were allow us to detect a difference in postoperative SMI at the receiving amlodipine, diltiazem, verapamil or felodipine.
5% level with a power of 85%. A similar calculation based Data from the ECG recorder were analysed using a comon the post hoc numbers of patients with postoperative SMI puter program designed for analysis of ST-segment changes in the exposed calcium channel entry blockade and unexposed (Medilog Prima ECG Analysis System). A significant episode control groups indicated that the study had 65% power to of ST-segment change was defined as horizontal or downslopdetect a difference at the 5% significance level. ing ST-segment depression of 1 mm or more, or ST-segment elevation of 2 mm or more lasting for 60 s or longer and followed by return to baseline for at least 1 min. Baseline was Results measured at a point 60 ms before the maximum R wave and Anaesthesia and surgery were uneventful in 454 patients; the ST-segment was measured at a point 100 ms after the there was one intraoperative death. Three patients died of maximum R wave. All recorded episodes of ST-segment acute myocardial infarction during the first 3 days after operachange were verified visually by one of the investigators.
tion. In two of these there were postoperative aECG data, and The choice of premedication, anaesthetic technique, posttherefore these patients were included in the analysis. In the operative analgesia, intensity of intraoperative monitoring third, aECG data were available for the preoperative but and postoperative oxygen therapy were at the discretion of not for the postoperative period, and this patient and the the anaesthetist and according to the surgery undertaken. All intraoperative death were excluded from further analysis. cardiovascular drugs were recommenced by the morning after Therefore, we analysed data from 453 patients, of whom 308 surgery unless the patient had a heart rate Ͻ50 beat min -1 or (68%) were male and 45% were aged more than 70 yr. a systolic arterial pressure Ͻ100 mm Hg.
Two hundred and fifty-one of 453 patients had coronary Patients were excluded from the study if their preoperative artery disease (previous myocardial infarct, typical angina or ECG revealed: evidence of left ventricular hypertrophy and atypical angina with a positive stress test) or two or more risk strain changes in the lateral chest leads; conduction defects; factors for coronary artery disease (age Ͼ70 yr, hypertension, changes caused by digoxin medication; or if there was inadcurrent smoker, hypercholesterolaemia, diabetes mellitus); equate data recording (Ͻ8 h) on any day in the pre-or 210 (46.4%) patients were receiving treatment for hypertenpostoperative period.
sion and 74 (16.3%) for ischaemic heart disease.
Statistical analysis
Seventy-nine (17.4%) patients were receiving chronic intercurrent β-adrenoceptor blockade for ischaemic heart disThe primary end-point of the study was the occurrence of postoperative SMI and its association with β-adrenoceptor ease or arterial hypertension on admission to hospital, and 70 (15.5 %) were receiving calcium channel entry blocking lysis. We examined for: the effects of confounding variables, as determined in Table 2 ; their effect on the coefficients of drugs. Twenty patients were receiving both β-blockade and calcium channel entry blocking medications. Seventy-eight the odds ratio of the association for β-adrenoceptor blockade and calcium channel entry blockade; and postoperative SMI. percent of patients were receiving β-adrenoceptor blocking drugs for hypertension, 5% for coronary artery disease and We also examined for any potential interaction between β-adrenoceptor blockade and calcium channel entry blockade, 12% for both; similarly, 63% of patients taking calcium channel entry blocking drugs were receiving treatment for hyper-and indications for the prescribing of these two drugs. However, there was no significant interaction between β-adrenotension, 13% for coronary artery disease and 24% for both. Fifty-nine of 79 patients receiving β-adrenoceptor blocking ceptor blockade and calcium channel entry blockade for the occurrence of postoperative SMI (odds ratio 2.48 (95% condrugs were receiving atenolol; others were receiving oxprenolol (one), bisoprolol (three), propranolol (six), metoprolol fidence intervals 0.71-8.73)).
The final coefficients for the best fit model are shown (five), labetolol (one) and sotalol (four). Fifty-three of 70 patients receiving calcium channel entry blocking drugs were in Table 3 . There was no effect of diabetes mellitus, sex, history of smoking, angina or past myocardial receiving nifedipine; others received amilodipine (six), diltiazem (six), verapamil (four) or felodipine (one). The age ranges infarction, or age greater than 70 yr. There were significant associations between calcium channel entry blockade and of the patient groups and indications for treatment, and other relevant cardiovascularly active therapies are shown in hypertension (odds ratio 9.32 (4.51-19.77)), calcium channel entry blockade and coronary artery disease Table 1 .
The association between the different variables and post-(angina or a past history of myocardial infarction) (5.01 (2.71-9.02)), and β-adrenoceptor blockade and operative SMI, as examined by univariate analysis, is shown in Table 2 . There was a significant association with four hypertension (21.05 (9.07-50.67)). variables: preoperative SMI, vascular surgery, arterial hypertension and intercurrent treatment with calcium channel entry Discussion blocking drugs. There was no effect of β-adrenoceptor blockade on postoperative SMI (Pϭ0.892). In 19 patients receiving In this re-analysis of observational data from four reported studies where the end-point was postoperative SMI, we both β-adrenoceptor and calcium channel entry blockers, 9 had no ECG changes associated with a perioperative SMI; found no effect of chronic intercurrent β-adrenoceptor blockade on the incidence of SMI, but noted an increased four had postoperative SMI and six had both pre-and postoperative SMI.
incidence of SMI in patients receiving chronic calcium channel entry blockade for either arterial hypertension or The data were then submitted to logistic regression ana- coronary artery disease. We chose to analyse our data in ence of ECG changes compatible with myocardial ischaemia of 0% (none of 14) vs 28% (11 of 39). However, this was the same manner as Mangano and colleagues, that is by comparing exposed patients (those receiving a particular a small study, and no patient had symptoms or clinical evidence of ischaemic heart disease. drug therapy) against unexposed patients (those not receiving that particular drug). Interactions between drugs and There were also differences between our patients and those reported by Wallace and colleagues. 10 We did not their effects on postoperative SMI were determined by logistic regression analysis.
confine our study to patients with ischaemic heart disease or to those with two or more risk factors, but chose to We have reported previously the effects of both a single oral premedicant dose of a β-adrenoceptor blocking drug examine a general non-cardiac surgical population. Thus the incidence of patients with either coronary arterial disease in mild untreated hypertensive patients and chronic intercurrent β-adrenoceptor blockade with atenolol in treated hyper-or 'at-risk' of coronary disease was 55.4% in our study compared with 100% in the studies of Mangano and tensive patients undergoing non-cardiac surgery under general anaesthesia. 7 8 There was a reduction in the incidence colleagues 9 and Wallace and colleagues. 10 There was also a significantly higher incidence of hypertension in association of observed ECG changes associated with myocardial ischaemia from 28% to 2%. Furthermore, the studies of with diabetes mellitus in the American series. There may be differences in the incidence and types of other preoperatMangano and colleagues and Wallace and colleagues also showed a reduction in perioperative SMI and mortality over ive drug therapies and in compliance with their administration, in addition to differences in the duration and conduct the first 2 yr after surgery. 9 10 In our patients undergoing non-cardiac surgical proced-of anaesthesia and surgery. Of additional concern is the fact that some patients in the Wallace study were receiving ures under general anaesthesia, those maintained on chronic intercurrent β-adrenoceptor blocking therapy did not show chronic β-adrenoceptor blockade which was stopped abruptly at the time of randomization-this may lead to the a reduction in the incidence of postoperative SMI. Why should our results be at variance with those of Stone and development of withdrawal features. 12 However, subsequent correspondence would suggest there were equal numbers colleagues 7 8 and Wallace and colleagues? 10 Compared with Stone and colleagues, 7 where untreated of patients where β-adrenoceptor blockade was withdrawn before operation in both treatment arms. patients with mild hypertension (diastolic pressure Ͻ100 mm Hg) received a single dose of a β-adrenoceptor blocking Diabetes mellitus is a powerful risk factor for atherosclerosis, especially if associated with arterial hypertension and drug with their premedication, patients in this meta-analysis continued to receive their normal β-adrenoceptor antagonist abnormalities of lipid metabolism (the so-called syndrome X). 13 Mangano and colleagues found three univariate premedication. Thus patients in our earlier study were different from the present group of patients, being mild-to-moderate dictors that influenced cardiac death: atenolol, diabetes mellitus and early postoperative SMI on days 0-2. 9 Atenolol untreated hypertensive patients (diastolic arterial pressure Ͻ100 mm Hg, with no ECG evidence of either left improved 2-yr survival in diabetic patients by approximately 75%; in the absence of β-adrenoceptor blockade, the relative ventricular hypertrophy or myocardial ischaemia) compared with patients with arterial hypertension or ischaemic heart odds ratio for adverse outcome from diabetes mellitus were increased four-fold. Moreover, with multivariate analysis, disease, or both. Chronic β-adrenoceptor treatment has been coupled with an increase in plasma high-density diabetes mellitus alone and not atenolol treatment was a predictor of cardiac outcome. lipoproteins, which may itself increase the incidence of latent ischaemic heart disease.
In a separate study, using multivariate logistic regression to define risk factors, Hollenberg and colleagues found In the second study by Stone and colleagues, 8 we compared patients maintained on β-adrenoceptor blocking drugs diabetes mellitus to be a predictor of postoperative SMI. 14 Thus diabetes may be a more important contributor towards with untreated controls, and showed a peroperative incid-cardiac complications than atenolol is in preventing it. The References incidence of diabetes mellitus in our patients was low 1 Muir AD, Reeder MK, Foex P, Ormerod OJM, Sear JW, (7.5%) compared with 31% in the study of Wallace and Johnston C. Preoperative silent myocardial ischaemia: incidence colleagues. 10 Hence any effect of β-adrenoceptor blockade and predictors in a general surgical population. Br J Anaesth 1991; 67: in improving outcome by reducing the influence of diabetes 2 Allman KG, Muir A, Howell SJ, Hemming AE, Sear JW, Foex P. mellitus might be expected to be small or insignificant. postoperative SMI and calcium channel entry blockade.
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The clinical significance of these findings clearly establishes 18 Psaty BM, Heckbert SR, Koepsell TD, et al. This work was supported by the Wellcome Trust.
